---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-009552"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T02:49:26.372365+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Merck Q4 GAAP EPS $1.18, revenue $13.8B; guides FY2023 non-GAAP EPS $6.80-$6.95

## Summary
- Q4 2022 GAAP EPS $1.18 (down 22% YoY); non-GAAP EPS $1.62 (down 10%); revenue $13.8B (+2%, +8% ex-FX).
- Full-year 2022 sales $59.3B (+22% YoY); KEYTRUDA $20.9B (+22%); GARDASIL $6.9B (+22%).
- FY2023 guidance: sales $57.2B-$58.7B (incl. ~$1B LAGEVRIO); GAAP EPS $5.86-$6.01; non-GAAP EPS $6.80-$6.95.
- Completed Imago BioSciences acquisition for $1.35B; new ADC collaboration with Kelun-Biotech.
- Regulatory: KEYTRUDA approved for adjuvant NSCLC; positive KEYNOTE-859 (gastric) and KEYNOTE-966 (biliary) data.

## SEC filing metadata
- accession: 0001104659-23-009552
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/0001104659-23-009552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/tm235007d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-009552
- JSON: https://secwatch.observer/filing/0001104659-23-009552.json
- Plain text: https://secwatch.observer/filing/0001104659-23-009552.txt

## Key facts
- Earnings Releases
  Merck & Co., Inc. reported Fourth-Quarter 2022 results: revenue $13.8 Billion, EPS $1.18; $1.62. Guidance initiated.
  - Period: Fourth-Quarter 2022
  - Revenue: $13.8 Billion
  - EPS: $1.18; $1.62
  - Guidance: initiated
  - Result: reported results
  source text: Fourth-Quarter 2022 Worldwide Sales Were $13.8 Billion, an Increase of 2% From Fourth Quarter 2021; Growth Excluding the Impact of Foreign Exchange Was 8% - Fourth-Quarter 2022 GAAP EPS From Continuing Operations Was $1.18; Fourth-Quarter 2022 Non-GAAP EPS Was $1.62
  evidence_url: https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/0001104659-23-009552-index.htm
- Earnings Releases
  Merck & Co., Inc. reported Full-Year 2022 results: revenue $59.3 Billion, EPS $5.71; $7.48. Guidance initiated.
  - Period: Full-Year 2022
  - Revenue: $59.3 Billion
  - EPS: $5.71; $7.48
  - Guidance: initiated
  - Result: reported results
  source text: Full-Year 2022 Worldwide Sales Were $59.3 Billion, an Increase of 22% From Full Year 2021; Growth Excluding LAGEVRIO Was 12%; Growth Excluding LAGEVRIO and the Impact of Foreign Exchange Was 15% o KEYTRUDA Sales Grew 22% to $20.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27% o GARDASIL/GARDASIL 9 Sales Grew 22% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27% - Full-Year 2022 GAAP EPS From Continuing Operations Was $5.71; Full-Year 2022 Non-GAAP EPS Was $7.48
  evidence_url: https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/0001104659-23-009552-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.